Clinical Endocrinology (1992) 36,45-52

Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study Helen M. Whitehead", Colin Borehamt. Edwln M. Mcllralh$, Brian Sheridan§, Laurence Kennedy*, A. Brew Atkinson' and David R. Hadden' *Sir George E . Clark Metabolic Unit, $Department of Radiology and §Regional Endocrine Laboratory, Royal Victoria Hospital, Belfast 6T72 6 6 A and t l h e Queen's University Physical Education Centre, Belfast, UK (Received 13 May 1991; returned for revision 19 June 1991; finally revised 7 August 1991; accepted 2 September 1991)

Summary OBJECTIVE We aimed to study the effect of biosynthetlc growth hormone (GH) replacement in growth hormone deficlent adults. DESIGN We performed a double-blind placebo-controlled cross-over study of 6 months biosynthetic GH, replacement and 6 months placebo separated by a 1-month's washout period. PATIENTS Fourteen growth hormone deficient adults were studied. MEASUREMENTS We measured total body weight, percentage fat mass, lean body mass, muscle volume, exercise capacity, maximum oxygen consumptlon, muscle strength, bone mineral contenl, a number of biochemical parameters, IGF-I, GH antlbodies and psychological well-being. RESULTS Total body welght remalned unchanged, but lean body mass increased (before GH mean f SEM 494 f 5.5, after 53.4f 5.6 kg; placebo before 51.2f 5.4, after 50.4f 5.1 kg; P < 0.05 and fat mass decreased (before GH 21.5h4.1,after 19.3f4.3;placebo before 19.3f4.0, after 22.53~43kg; Pi0.05). Thigh muscle volume Increased: (before GH 94.1f7.7,after 995f8.4 ml; placebo before 99.3f 8.6,after 95.4f 7.8 m1/04 mm computerized tomographic slice; P < 0.05). Exerclse capacity increased (before GH 174f15, after 199f18.9 watts; placebo before 162.5f 23,after 154f 19.8watts; P < 0.05), as did maximum oxygen consumption (before OH 1.93f 0.2, after 2.17f 0.2 I/m; placebo before 1.92f 0.3, after 1.98f 0.2 I/m; P < 0.05). There was no change in quadrlceps muscle strength. Alkallne phosphatase Correspondence: Helen M . Whitehead, Sir George E. Clark Metabolic Unit, Royal Victoria Hospital, Belfast BT12 6BA, UK.

increased (before GH 87.5(32-158),after 106.0(49-179)U/ I; placebo 99.5 (50-145),after 72.0 (40-111) UII; P

Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study.

We aimed to study the effect of biosynthetic growth hormone (GH) replacement in growth hormone deficient adults...
700KB Sizes 0 Downloads 0 Views